Trial Profile
A randomized, placebo-controlled Phase 3 study of VY-AADC in patients with Parkinson's disease
Status:
Planning
Phase of Trial:
Phase III
Latest Information Update: 19 Jul 2018
Price :
$35
*
At a glance
- Drugs Ezaladcigene resoparvovec (Primary)
- Indications Parkinson's disease
- Focus Registrational; Therapeutic Use
- 19 Jul 2018 New trial record
- 17 Jul 2018 According to a Voyager Therapeutics media release, based on the feedback from a Type 2 meeting with the US FDA, the company plans to submit review a biologics license application (BLA) for VY-AADC based on the data of phase 2 study (297013). However, if the result from this study is supportive and did not met its primary endpoint, the BLA application will be also supported by this study, if able to achieve primary endpoint.